Cancer Drug Delivery Systems Using Bacterial Toxin Translocation Mechanisms
Open Access
- 7 July 2023
- journal article
- review article
- Published by MDPI AG in Bioengineering
- Vol. 10 (7) , 813
Abstract
Recent advances in targeted cancer therapy hold great promise for both research and clinical applications and push the boundaries in finding new treatments for various currently incurable cancers. However, these therapies require specific cell-targeting mechanisms for the efficient delivery of drug cargo across the cell membrane to reach intracellular targets and avoid diffusion to unwanted tissues. Traditional drug delivery systems suffer from a limited ability to travel across the barriers posed by cell membranes and, therefore, there is a need for high doses, which are associated with adverse reactions and safety concerns. Bacterial toxins have evolved naturally to specifically target cell subtypes via their receptor binding module, penetrating the cell membrane efficiently through the membrane translocation process and then successfully delivering the toxic cargo into the host cytosol. They have, thus, been harnessed for the delivery of various drugs. In this review, we focus on bacterial toxin translocation mechanisms and recent progress in the targeted delivery systems of cancer therapy drugs that have been inspired by the receptor binding and membrane translocation processes of the anthrax toxin protective antigen, diphtheria toxin, and Pseudomonas exotoxin A. We also discuss the challenges and limitations of these studies that should be addressed before bacterial toxin-based drug delivery systems can become a viable new generation of drug delivery approaches in clinical translation.Keywords
Funding Information
- National Institutes of Health (R01NS080833, R01AI132387, R01AI139087, P30DK034854, P30HD18655)
- Office of Faculty Development at Harvard Medical School (R01NS080833, R01AI132387, R01AI139087, P30DK034854, P30HD18655)
- NIH-funded Harvard Digestive Disease Center (R01NS080833, R01AI132387, R01AI139087, P30DK034854, P30HD18655)
- Boston Children’s Hospital Intellectual and Developmental Disabilities Research Center (R01NS080833, R01AI132387, R01AI139087, P30DK034854, P30HD18655)
- Harvard Center for Glycoscience (R01NS080833, R01AI132387, R01AI139087, P30DK034854, P30HD18655)
This publication has 101 references indexed in Scilit:
- Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based onPseudomonasexotoxin AProceedings of the National Academy of Sciences, 2012
- Changing the Receptor Specificity of Anthrax ToxinmBio, 2012
- Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastomaNeuro-Oncology, 2010
- Receptors of anthrax toxin and cell entryMolecular Aspects of Medicine, 2009
- Membrane translocation by anthrax toxinMolecular Aspects of Medicine, 2009
- The Protective Antigen Component of Anthrax Toxin Forms Functional Octameric ComplexesJournal of Molecular Biology, 2009
- CAT-8015: A Second-GenerationPseudomonasExotoxin A–Based Immunotherapy Targeting CD22-Expressing Hematologic MalignanciesClinical Cancer Research, 2009
- Matrix Metalloproteinase-activated Anthrax Lethal Toxin Demonstrates High Potency in Targeting Tumor VasculatureJournal of Biological Chemistry, 2008
- Anthrax Toxin Receptor 2 Determinants that Dictate the pH Threshold of Toxin Pore FormationPLOS ONE, 2007
- SV2 Is the Protein Receptor for Botulinum Neurotoxin AScience, 2006